Key Highlights

  • Hims & Hers (HIMS) shares fell 8.01% to $31.08 after the FTC, joined by Utah and California, filed suit alleging the company shared sensitive health data in violation of privacy commitments.
  • Second-quarter Revenue of $753.2 million represented 38% year-over-year growth, with subscriber count rising 19% to 2.89 million.
  • The company swung to a net loss of $86.3 million in the quarter, compared with Net Income of $42.5 million in the prior-year period.
  • Chief Accounting Officer Irene Becklund will depart effective October 9, 2026, with CFO Yemi Okupe assuming interim responsibilities for that function.

Hims & Hers Health, Inc. (NYSE:HIMS) shares fell 8.01% to $31.08 in the latest closing session, placing the stock among the day's most notable decliners.

What Happened

Hims & Hers Health, Inc. (HIMS) shares fell 8.01% to $31.08 in the latest closing session, as a federal privacy lawsuit weighed on the stock despite strong underlying growth.

The Latest Company Catalyst

The clearest verified catalyst in recent weeks is regulatory rather than financial. On July 29, 2026, the Federal Trade Commission, joined by the states of Utah and California, filed suit against Hims & Hers alleging the company shared consumers' sensitive health information in violation of privacy commitments, characterizing the practices as deceptive and unlawful. Hims & Hers subsequently filed a public response disputing the characterization of its conduct.

That announcement corresponded with the sharpest single-day decline in the stock over the period reviewed, underscoring how seriously investors are weighing the legal and reputational risk facing a company whose Business model depends on consumer trust around sensitive health data. Separately, the company unveiled a rebuilt Hers app with AI-native, doctor-led care features for weight-loss members, including a complimentary smart scale, though that product news was also followed by share-price weakness.

Financial Position

Hims & Hers' underlying growth metrics remain robust. Second-quarter revenue of $753.2 million represented 38% year-over-year growth, and subscriber count rose 19% to 2.89 million. However, the company swung to a net loss of $86.3 million in the quarter, compared with net income of $42.5 million in the prior-year period, a Reversal that has drawn scrutiny even as management raised full-year revenue and adjusted EBITDA guidance.

Analysts covering the stock have flagged that subscriber growth, while impressive, has not been sufficient to offset continued gross-margin slippage, a dynamic that can weigh on a stock trading at a premium growth multiple even when top-line results beat expectations. The company also disclosed the departure of its Chief Accounting Officer, Irene Becklund, effective October 9, 2026, with Chief Financial Officer Yemi Okupe assuming interim responsibilities for that function.

The Investment Story

Hims & Hers built its market position on direct-to-consumer telehealth, particularly in weight-management, sexual health, and dermatology categories, with GLP-1 weight-loss offerings a significant growth driver over the past two years. The bull case rests on continued subscriber expansion, improving unit Economics as scale builds, and expansion into new care categories.

The bear case centers on Margin compression as the company invests in customer Acquisition and clinical infrastructure, intensifying competition from both legacy pharmacy benefit players and other telehealth entrants, and now, acutely, Regulatory Risk tied to how the company handles consumer health data, a risk that strikes directly at the trust-based nature of its business model.

What Could Be Worrying Investors

The FTC and state-level privacy lawsuit introduces legal costs, potential penalties, and reputational risk that are difficult to quantify but clearly material to a healthcare-adjacent consumer brand. The shift from net income to a substantial net loss, even amid revenue growth, raises questions about the durability of profitability as the company scales.

After a run of more than 100% over six months, some of the decline may simply reflect profit-taking and valuation reset as growth investors rotate out of richly priced names. The accounting Leadership departure, even if procedurally routine, can unsettle investors already nervous about margin transparency.

What Investors Should Watch Next

Investors should track the FTC litigation's progression, including any settlement talks, discovery developments, or rulings that could clarify the company's financial exposure. The transition of accounting oversight to CFO Yemi Okupe through early October, and any permanent CAO hire, will be worth monitoring for signs of stability.

Third-quarter results will show whether the company can narrow its net loss while sustaining subscriber growth. Analyst price target revisions, currently spanning roughly $23 to $42 with an average near $30.85, may shift materially depending on how the legal matter and margin trends evolve.

Strong Growth Meets a Serious Privacy Case

Hims & Hers presents a genuinely mixed picture: a company growing revenue and subscribers at an impressive clip while simultaneously absorbing a swing to net losses, a serious federal and state privacy lawsuit, and leadership transition in its accounting function. The stock's sharp pullback from its 2026 highs suggests the market is pricing in real uncertainty around margins and regulatory exposure rather than merely reacting to noise.

Whether the current weakness represents an overcorrection of a strong growth story or a fair repricing of newly visible risks is not yet resolved, and investors weighing the name should watch the FTC case and upcoming quarterly results closely.